GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

The future facility will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. As a ...

Medicago’s plant-derived vaccine candidate against COVID ... co-administered with GSK’s pandemic adjuvant. Two doses of 3.75 micrograms of the vaccine are administered 21 days apart.

CDMO Rentschler Biopharma is signalling its intent to cut down cell and gene therapy operations by shutting down its UK ...

January 13, 2025--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

The pipeline will run for about 213 kilometres to a $7.4 billion polyethylene plant where construction started last September ...

Lacalle Pou “welcomed GSK's announcement of the opening of one ... will concentrate the products manufactured in its different plants in Europe. Nevertheless, the agreement between GSK and ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The purchase ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal cancer asset. “We really became impressed with what IDRx had achieved ...